Predicted protein targets (top 18)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SCN9A | Q15858 | 1/20 | 0.46 |
| ▸ | L3MBTL1 | Q9Y468 | 2/20 | 0.44 |
| ▸ | NPC1 | O15118 | 1/20 | 0.44 |
| ▸ | RAB9A | P51151 | 1/20 | 0.44 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.44 |
| ▸ | POLB | P06746 | 1/20 | 0.44 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.44 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.44 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.44 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.43 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.43 |
| ▸ | HTT | P42858 | 1/20 | 0.43 |
| ▸ | MCL1 | Q07820 | 1/20 | 0.43 |
| ▸ | MAPT | P10636 | 4/20 | 0.43 |
| ▸ | TP53 | P04637 | 1/20 | 0.43 |
| ▸ | RARA | P10276 | 1/20 | 0.43 |
| ▸ | RARB | P10826 | 1/20 | 0.43 |
| ▸ | RARG | P13631 | 1/20 | 0.43 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4462347 | 0.96 | NPC1 (0.47) | L3MBTL1NPC1RAB9ASMN1; SMN2ALDH1A1 | |
| SCHEMBL4684167 | 0.87 | MCL1 (0.50) | MCL1 | |
| SCHEMBL4686964 | 0.84 | MCL1 (0.46) | L3MBTL1NPC1RAB9APOLBSMN1; SMN2 | |
| SCHEMBL4681552 | 0.82 | NR4A2 (0.49) | NPC1RAB9ASMN1; SMN2MCL1 | |
| SCHEMBL4460360 | 0.82 | LTA4H (0.47) | NPC1RAB9ACYP1A2CYP2C19SMN1; SMN2 | |
| Trifluoroacetic Acid SCHEMBL4460353 | 0.81 | MCL1 (0.47) | MCL1 | |
| SCHEMBL4455245 | 0.81 | NPC1 (0.50) | L3MBTL1NPC1RAB9ASMN1; SMN2ALDH1A1 | |
| SCHEMBL4685016 | 0.81 | GAA (0.47) | L3MBTL1RAB9ASMN1; SMN2ALDH1A1HTT | |
| SCHEMBL4457369 | 0.80 | MEN1 (0.48) | CYP1A2POLBCYP2C19ALDH1A1TDP1 | |
| SCHEMBL4456543 | 0.80 | MCL1 (0.54) | L3MBTL1NPC1RAB9ACYP1A2POLB |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7534805-B2 | Imidazole derivatives, their preparation and their use as medicaments | SOCIETE DE CONSEILS DE RECHERCHES ET D'APPLICATIONS SCIENTIFIQUES (S.C.R.A.S.) (FR) | 2009-05-19 | — | — | US | claimed |
| EP-1638943-B1 | NOVEL IMIDAZOLE DERIVATIVES, THE PRODUCTION THEREOF, AND THE USE OF THE SAME AS A MEDICAMENT | SOD CONSEILS RECH APPLIC (FR) | 2008-08-06 | — | — | EP | claimed |
| US-20070066542-A1 | Novel imidazole derivatives, their preparation and their use as medicaments | SOCIETE DE CONSEILS DE RECHERCHES ET D'APPLICATION SCIENTIFIQUES (S.C.R.A.S.) (FR) | 2007-03-22 | — | — | US | claimed |
| US-7534805-B2 | Imidazole derivatives, their preparation and their use as medicaments | SOCIETE DE CONSEILS DE RECHERCHES ET D'APPLICATIONS SCIENTIFIQUES (S.C.R.A.S.) (FR) | 2009-05-19 | — | — | US | disclosed |
| US-20070066542-A1 | Novel imidazole derivatives, their preparation and their use as medicaments | SOCIETE DE CONSEILS DE RECHERCHES ET D'APPLICATION SCIENTIFIQUES (S.C.R.A.S.) (FR) | 2007-03-22 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070066542-A1 | Novel imidazole derivatives, their preparation and their use as medicaments | MIF, MCL1, PPIP5K2 | SCN9A 4438/4885L3MBTL1 4696/4885NPC1 512/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.